Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-278-8930
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees321
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) released its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.45) by $0.15. View Atara Biotherapeutics' Earnings History.
When is Atara Biotherapeutics' next earnings date?
What price target have analysts set for ATRA?
9 Wall Street analysts have issued 1 year target prices for Atara Biotherapeutics' shares. Their forecasts range from $14.00 to $70.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $34.6667 in the next year. This suggests a possible upside of 119.3% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.
What is the consensus analysts' recommendation for Atara Biotherapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.
What are Wall Street analysts saying about Atara Biotherapeutics stock?
Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (7/16/2019)
- 2. William Blair analysts commented, "We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant." (4/1/2019)
- 3. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)
Has Atara Biotherapeutics been receiving favorable news coverage?
Media coverage about ATRA stock has been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atara Biotherapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Atara Biotherapeutics.
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Regenxbio (RGNX), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Atara Biotherapeutics own?
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
- Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
- Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
- Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)
Who are Atara Biotherapeutics' major shareholders?
Atara Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baupost Group LLC MA (13.02%), BlackRock Inc. (7.15%), Vanguard Group Inc. (5.60%), Maverick Capital Ltd. (4.15%), Morgan Stanley (3.72%) and JPMorgan Chase & Co. (4.06%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Gad Soffer, Heather D Turner, Isaac E Ciechanover, Joe Newell, Joel S Marcus, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.
Which institutional investors are selling Atara Biotherapeutics stock?
ATRA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Cormorant Asset Management LP, TD Asset Management Inc., JPMorgan Chase & Co., Northern Trust Corp, Tiverton Asset Management LLC, BNP Paribas Arbitrage SA and Elkfork Partners LLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Isaac E Ciechanover, Joe Newell and Joel S Marcus. View Insider Buying and Selling for Atara Biotherapeutics.
Which institutional investors are buying Atara Biotherapeutics stock?
ATRA stock was bought by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Morgan Stanley, Baupost Group LLC MA, BlackRock Inc., Nuveen Asset Management LLC, Wasatch Advisors Inc., Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier and Utpal Koppikar. View Insider Buying and Selling for Atara Biotherapeutics.
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $15.81.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $849.95 million. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.View Additional Information About Atara Biotherapeutics.
What is Atara Biotherapeutics' official website?
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
